Anavex Life Sciences Corp (AVXL)

[falconer66a]

Yes! At the start of the causal chain.

The "magic" is moving upstream in the causal chain. It appears Blarcamesine may do just that.

Succinctly, that’s it. Uniquely, blarcamesine starts its work at the top, at the beginning of the various reaction chains and biochemical processes that control and modulate how a cell functions.

That’s the seminal difference between blarcamesine and the other prospective new drugs targeting Alzheimer’s and the other CNS diseases. They address “downstream” anomalies, often just the symptoms they cause. The actual primal, root causes continue, with little persisting abatement. Sooner or later, they prevail and the Alzheimer’s patient meets the universal lethal fate of the disease.

If a car’s engine has big oil leaks, from fatiguing metals, one can continue to add more oil to the crankcase to keep things opperating. But eventually, the weakened, leaking sheet metal in the oil pan finally breaks wide open. The engine is terminated.

The root, “upstream” cause was bad, weak sheet metal in the oil pan. Until a new oil pan, with strong sheet metal is installed, adding make-up oil will be a continuing obligation; until the oil pan fails altogether.

Thanks. A perfect, descriptive phrase: “Blarcamesine works propitiously upstream, at the start of the ‘casual chain.’”